Erythroid-specific human factor IX delivery from In vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice Journal Article


Authors: Chang, A. H.; Stephan, M. T.; Lisowski, L.; Sadelain, M.
Article Title: Erythroid-specific human factor IX delivery from In vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice
Abstract: We have developed a lentiviral vector system for human factor IX (hFIX) gene transfer in hematopoietic stem cells (HSCs) that provides erythroid cell-derived systemic protein delivery following nonmyeloablative conditioning and in vivo methylguanine methyltransferase (MGMT) drug selection. After bone marrow transplantation under moderate Busulfan conditioning, the initial hFIX expression in the chimeras was minimally detectable. However, the hFIX levels rose sharply following in vivo MGMT-drug selection and eventually reached a level that is considered curative in hemophilia B therapy (>500 ng/ml). The rise of hFIX levels was proportional to the increase in vector copy (VC) number in peripheral blood cells. High levels of hFIX expression were maintained in serially engrafted mice chimeras for 18 months. Importantly, high-level hFIX expression by erythroid cells did not result in anemia or adversely affect red blood cell counts. The prospect of combining reduced intensity conditioning, a presumably lowered risk of insertional mutagenesis due to low VC number requirement and erythroid-restricted transgene expression, as well as long-term protein expression at high level, strongly supports the potential applicability of adult stem cell-based gene therapy in nonlethal blood or metabolic disorders, as demonstrated here for hemophilia.
Keywords: controlled study; protein expression; unclassified drug; busulfan; nonhuman; protein blood level; animal cell; mouse; animals; mice; mus; anemia; animal experiment; animal model; hematopoietic stem cell transplantation; in vivo study; mice, inbred c57bl; carmustine; cell specificity; gene transfer; genetic vectors; methyltransferase; engraftment; nonmyeloablative conditioning; tumor suppressor proteins; recombinant proteins; lentivirus; lentivirus vector; erythroid cell; reduced intensity conditioning; stem cell gene therapy; hematopoietic stem cells; dna repair enzymes; homeostasis; dna modification methylases; virus particle; mutagenesis; blood clotting factor 9; 6 o benzylguanine; hemophilia b; factor ix; histocompatibility; erythrocyte count; methylguanine methyltransferase
Journal Title: Molecular Therapy
Volume: 16
Issue: 10
ISSN: 1525-0016
Publisher: Nature Publishing Group  
Date Published: 2008-01-01
Start Page: 1745
End Page: 1752
Language: English
DOI: 10.1038/mt.2008.161
PUBMED: 18682698
PROVIDER: scopus
PMCID: PMC2658893
DOI/URL:
Notes: --- - "Cited By (since 1996): 9" - "Export Date: 17 November 2011" - "CODEN: MTOHC" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Alex Hongsheng Chang
    9 Chang
  2. Michel W J Sadelain
    489 Sadelain